{"id":"igiv3i-grifols-10","safety":{"commonSideEffects":[{"rate":null,"effect":"Headache"},{"rate":null,"effect":"Fever"},{"rate":null,"effect":"Chills"},{"rate":null,"effect":"Myalgia"},{"rate":null,"effect":"Infusion reactions"},{"rate":null,"effect":"Thrombosis"}]},"_chembl":{"chemblId":"CHEMBL513978","moleculeType":"Small molecule","molecularWeight":"372.51"},"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"IGIV3I 10% is a human immune globulin intravenous (human) preparation derived from pooled plasma of multiple donors. It functions by supplying exogenous immunoglobulins that can neutralize pathogens, opsonize antigens, modulate complement activation, and regulate inflammatory immune responses through Fc receptor engagement on immune cells.","oneSentence":"IGIV3I is an intravenous immunoglobulin (IVIG) product that provides passive immunity by delivering pooled human antibodies to modulate immune responses and provide immunoprotection.","_ai_confidence":"medium"},"_scrapedAt":"2026-03-28T01:15:31.596Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Primary immunodeficiency disorders"},{"name":"Secondary immunodeficiency"},{"name":"Autoimmune and inflammatory conditions (e.g., immune thrombocytopenia, chronic inflammatory demyelinating polyneuropathy)"}]},"trialDetails":[{"nctId":"NCT00511147","phase":"PHASE3","title":"IGIV Study for Chronic ITP Patients Ages 3-70","status":"COMPLETED","sponsor":"Grifols Biologicals, LLC","startDate":"2008-05","conditions":"Idiopathic Thrombocytopenic Purpura","enrollment":64},{"nctId":"NCT00699140","phase":"PHASE3","title":"Clinical Trial in Patients Diagnosed With Immune Thrombocytopenic Purpura","status":"COMPLETED","sponsor":"Instituto Grifols, S.A.","startDate":"2008-02","conditions":"Immune (Idiopathic) Thrombocytopenic Purpura","enrollment":18}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":1236,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["Intravenous immunoglobulin"],"phase":"phase_3","status":"active","brandName":"IGIV3I Grifols 10%","genericName":"IGIV3I Grifols 10%","companyName":"Grifols Biologicals, LLC","companyId":"grifols-biologicals-llc","modality":"Biologic","firstApprovalDate":"","aiSummary":"IGIV3I is an intravenous immunoglobulin (IVIG) product that provides passive immunity by delivering pooled human antibodies to modulate immune responses and provide immunoprotection. Used for Primary immunodeficiency disorders, Secondary immunodeficiency, Autoimmune and inflammatory conditions (e.g., immune thrombocytopenia, chronic inflammatory demyelinating polyneuropathy).","enrichmentLevel":3,"visitCount":1,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}